[{"uuid": "4eaabc49-af68-3789-9c05-eca3a9a2b492", "title": "Chronic Pain Clinical Trial Pipeline Experiences Momentum: DelveInsight Estimates a Diverse Pipeline Comprising 20+ Companies Working in the Domain", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/chronic-pain-clinical-trial-pipeline-180000518.html", "providerPublishTime": 1738260000, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/bh3NjP1sbit4qDYmEa0_5Q--~B/aD0xNzc0O3c9NzAyNDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/77011be1a12431fff8ed0ec458d52eca", "width": 7024, "height": 1774, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/cjcUP0yK3xNDIg5A8x9c8w--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/77011be1a12431fff8ed0ec458d52eca", "width": 140, "height": 140, "tag": "140x140"}]}}, {"uuid": "d7c49511-4687-38a9-ad4c-c028fda9689e", "title": "Context Therapeutics Doses First Patient in Phase 1 Cancer Treatment Trial", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/context-therapeutics-doses-first-patient-223721335.html", "providerPublishTime": 1736894241, "type": "STORY", "relatedTickers": ["CNTX"]}, {"uuid": "0f0caa10-aba6-32dc-8e99-eeac54e76269", "title": "Context Therapeutics Announces First Patient Dosed in the Phase 1 Clinical Trial of CTIM-76", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/context-therapeutics-announces-first-patient-215800413.html", "providerPublishTime": 1736891880, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/IdoONhPWxMgW8UNRadv3bQ--~B/aD0yMjY7dz00ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc", "width": 485, "height": 226, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pZCgA84EH4Gj0vF5Lqfmog--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CNTX"]}, {"uuid": "f7412c2a-5e5b-3ffd-bcd4-a55e6206e24e", "title": "Sector Update: Health Care Stocks Rise Premarket Wednesday", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-141552218.html", "providerPublishTime": 1736950552, "type": "STORY", "relatedTickers": ["KROS"]}, {"uuid": "2eccce15-9bd1-3c0b-bcef-5f974ea1196d", "title": "Context Therapeutics Names Andy Pasternak Board Chairman", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/context-therapeutics-names-andy-pasternak-133012190.html", "providerPublishTime": 1736775012, "type": "STORY", "relatedTickers": ["CNTX"]}, {"uuid": "3318eed8-2bf4-39a3-b167-ddcac36ed3c6", "title": "Context doses first subject in Phase I cancer trial of CTIM-76", "publisher": "Clinical Trials Arena", "link": "https://finance.yahoo.com/m/3318eed8-2bf4-39a3-b167-ddcac36ed3c6/context-doses-first-subject.html", "providerPublishTime": 1736958570, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/FRw.gCBqCKcGmPDe_VnqHQ--~B/aD05NjA7dz0xNDQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/2618b8543af5b01b31f2f9f393304d84", "width": 1440, "height": 960, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/3vChKhSK4HSJIBtzTfnpUg--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/clinical_trials_arena_396/2618b8543af5b01b31f2f9f393304d84", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CNTX"]}, {"uuid": "ce6d02e2-2c40-3487-8987-a1347a070f30", "title": "Context Therapeutics Appoints Andy Pasternak as Chairman of the Board of Directors", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/context-therapeutics-appoints-andy-pasternak-123000238.html", "providerPublishTime": 1736771400, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/IdoONhPWxMgW8UNRadv3bQ--~B/aD0yMjY7dz00ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc", "width": 485, "height": 226, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pZCgA84EH4Gj0vF5Lqfmog--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CNTX"]}, {"uuid": "9c4ffdb9-a5f0-3f35-8a64-485df99f8be4", "title": "JMP Securities Initiates Context Therapeutics at Outperform With $4 Price Target", "publisher": "MT Newswires", "link": "https://finance.yahoo.com/news/jmp-securities-initiates-context-therapeutics-143258430.html", "providerPublishTime": 1736346778, "type": "STORY", "relatedTickers": ["CNTX"]}, {"uuid": "b977373a-62ce-3a7b-aacc-26dbc62d82b3", "title": "Context Therapeutics Reports Third Quarter 2024 Operating and Financial Results", "publisher": "GlobeNewswire", "link": "https://finance.yahoo.com/news/context-therapeutics-reports-third-quarter-210600893.html", "providerPublishTime": 1730927160, "type": "STORY", "thumbnail": {"resolutions": [{"url": "https://s.yimg.com/uu/api/res/1.2/IdoONhPWxMgW8UNRadv3bQ--~B/aD0yMjY7dz00ODU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc", "width": 485, "height": 226, "tag": "original"}, {"url": "https://s.yimg.com/uu/api/res/1.2/pZCgA84EH4Gj0vF5Lqfmog--~B/Zmk9ZmlsbDtoPTE0MDtweW9mZj0wO3c9MTQwO2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/globenewswire.com/2ecf57f3dc7765bd8c5cadbf95373ccc", "width": 140, "height": 140, "tag": "140x140"}]}, "relatedTickers": ["CNTX"]}]